None listed
Conditions
Interventions
Drug : Under endoscopic guidance, inject 4 cc (50 mg/cc) of 5-FU 200 mg using an injector needle into the normal tissue surrounding the mass in 0.5 cc increments, 4 proximal (100 mg) and 4 distal (100
Sponsors
Kangbuk Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 18 years or older with histologically confirmed adenocarcinoma and diagnosed with advanced gastric cancer that is not amenable to radical resection at the time of diagnosis who meet the following conditions are eligible. Patients who have failed standard treatment or for whom standard treatment is not feasible, Patients with measurable lesions in the stomach on endoscopy, Patients with a predicted survival time of 3 months or more.
Exclusion criteria
Exclusion criteria: ? Patients with a history of cancer other than gastric cancer ? Patients who do not consent to this treatment ? Nursing mothers other than pregnant women or women of childbearing potential who are planning to become pregnant ? Patients receiving Tegapur-Gimeracil-Oterasil potassium combination and patients who have stopped taking it within 7 days. ? Patients receiving sorbudine ? Patients with a history of severe hypersensitivity to 5-FU ? Patients with bone marrow depression after treatment with other antineoplastic agents, radiation therapy, or extreme frailty ? Patients with non-malignant tumor disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR; objective response rate): Percentage of patients with an objective response, such as a reduction in tumor size, relative to the total number of patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in tumor size and area on endoscopy | — |
Countries
Korea, Republic of
Contacts
Public ContactJiae Lee
Kangbuk Samsung Medical Center
Outcome results
None listed